article · 2018
Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376)
To assess the effect of ocrelizumab compared to placebo on T1 hypo-intense volume and mean T1-intensity of slowly evolving lesions (SELs) in patients with pr...
1 citationsDOI: https://doi.org/10.1212/wnl.90.15_supplement.p3.376